It’s well known that America spends more and gets less for its health care dollar than peer countries, and has for a while. Where does all the money go? A recent research letter in JAMA Internal Medicine shows how much of healthcare industry profits are directed to corporate shareholders. More
The list of ten drugs for Medicare price negotiation has been published! What do we know about these Medicare "blockbusters"? And how are drugmakers taking the news? More
If you want to see an epic battle between hospitals and pharma, look no further than the 340B drug discount program. Why is this program so controversial, and what do new studies show about its effectiveness? More
Unlike its predecessor drug aducanumab, lecanemab actually showed a statistically significant difference in slowing cognitive decline in its clinical trial. But can the drug improve patients’ quality of life? More
Two recent analyses of expensive medications indicate that many drugs are being priced above their actual clinical benefit. More
Insulin manufacturer Eli Lilly announced that it would be cutting the list price of its generic insulin products significantly. This move comes after decades of advocacy work by patients and clinicians alike, including our sister organization the Right Care Alliance. What does this tell us about the drug pricing landscape? More
With $8 and 9 words, one internet troll is forcing insulin manufacturers to answer the question of why the drug is so unaffordable More
What could be a fruitful conversation on racial equity is being co-opted by pharmaceutical companies to sell unproven drugs. More
Skipping doses, intentionally undermedicating, not eating - these are all measures 1.3 million Americans are forced to take to keep their insulin costs down. More
The reasoning behind this decision has to do with a complex bioethical question - if there is the potential to treat a previously untreatable disease with a new pharmaceutical, but the consequences are unknown, do you prescribe the drug? Is the unknown enough to deny patients hope? More
The Inflation Reduction Act allows Medicare to negotiate drug prices and cap insulin costs...but only for Medicare enrollees. More
A telehealth company's downfall sheds light on the overprescription of stimulants to ADHD patients More
After CMS restricted access to Aduhelm, Biogen and the Alzheimer's Association called the decision discriminatory. Here's why we're skeptical... More
A recently-released Congressional committee report on drug prices reveals some outrageous business practices by pharma -- here's what they found. More
A recent Reuters investigation found that a campaign to lower the A1c target for diabetes was driven largely by pharmaceutical companies, to create a bigger market for their new blood sugar-lowering drugs. More
Has pharma cracked the secret code to profit through cancer drugs? A recent study takes a closer look at the impact of cancer drug prices on pharma revenues. More
Despite larger health threats consuming the nation this year, pharma did not let up on their fear-mongering advertisements. Check out a few of the scariest-- if you dare! More
Experts weigh in on the recently revealed price of Covid-19 drug remdesivir. More
How much should remdesivir cost? This question puts two drug-value organizations at odds. More
The pharmaceutical industry often justifies high drug prices by claiming that they create more innovation, but two recent studies find that drug costs and clinical benefit are often not related. More